Apellis Pharmaceuticals Achieves Profitability in 2025 with Strong Revenue Growth and Strategic Deals

summarizeSummary

Apellis Pharmaceuticals achieved net income of $22.4 million in 2025, a significant turnaround from previous losses, driven by strong total revenue growth and a major upfront payment from a Sobi royalty agreement, despite a European regulatory setback for SYFOVRE.

check_boxKey Events

• Achieved Net Income in 2025

  The company reported a net income of $22.4 million for the year ended December 31, 2025, a significant improvement from net losses of $197.9 million in 2024 and $528.6 million in 2023.

• Strong Total Revenue Growth

  Total revenue increased to $1,003.8 million in 2025, up from $781.4 million in 2024, primarily due to a substantial increase in licensing and other revenue.

• Significant Sobi Royalty Buy-Down Payment

  Apellis received a $275.0 million upfront payment from Sobi under a Royalty Buy-Down Agreement in July 2025, with an additional $25.0 million milestone received in February 2026 following EMA approval of Aspaveli for C3G and primary IC-MPGN.

• EMPAVELI Approved for New Indications

  The FDA approved EMPAVELI for the treatment of C3 glomerulopathy (C3G) and primary immune complex membranoproliferative glomerulonephritis (primary IC-MPGN) in July 2025, and pivotal trials for FSGS and DGF were initiated in Q4 2025.

auto_awesomeAnalysis

Apellis Pharmaceuticals reported a significant financial turnaround in 2025, achieving a net income of $22.4 million, a substantial improvement from net losses in prior years. This shift was primarily driven by a robust increase in total revenue to over $1 billion, significantly boosted by a $275.0 million upfront payment from a Royalty Buy-Down Agreement with Sobi. The company also saw continued product development progress, including FDA approval for EMPAVELI in C3G and primary IC-MPGN, and positive 5-year data for SYFOVRE. However, the European Commission's rejection of SYFOVRE's marketing authorization application in December 2024 presents a notable setback for international expansion. Additionally, $93.9 million in convertible notes are now classified as current liabilities, requiring attention in the near term. Despite these challenges, the overall financial performance marks a critical positive inflection point for the company.